Clerio Vision Hires Eye Care Industry Veteran to Lead Cornea Commercialization Efforts

Teaser Text: John Weberg joins ophthalmic technology firm to fuel growth.

Category: Portfolio News

ROCHESTER, N.Y. (PRWEB) – October 07, 2019 – Clerio Vision has named John Weberg as Cornea Chief Commercialization Officer to further expand the development of its cornea business, which includes continued research and development, clinical trials and commercialization efforts.

The company expects to use its Laser Induced Refractive Index Correction (LIRIC) technology to offer superior Fresnel lens diffractive optics patterns to correct presbyopia, myopia, hyperopia, astigmatism and higher order aberrations.  

“The technology that Clerio Vision is bringing forth will be so disruptive to ophthalmology, that it will revolutionize how we do business and change people’s lives for the better by offering a safe, noninvasive solution for most if not all the refractive diseases,” Weberg said. “I believe this technology will be seen as a significant life changing therapy for patients with a giant leap forward in safety and efficacy. ”

Weberg, who most recently was global director of medical affairs for Johnson & Johnson’s surgical business, brings an in-depth knowledge of healthcare operations at all levels, from startup ventures to Fortune 100 companies. He is also known for his efforts at Visx, a refractive surgery provider, a company which was purchased by Advanced Medical Optics in a $1.27 billion deal in 2004.

“We are extremely pleased to have John on board,” said Alex Zapesochny, CEO of Clerio. “His leadership and expertise in this industry, in building and growing Visx’s markets, will greatly enhance our strategies and execution as we propel Clerio forward.”

 

About Clerio Vision, Inc.

Clerio Vision is developing a revolutionary product platform for the global ophthalmic market, based on technology licensed from the University of Rochester.  The company’s contact lens and refractive surgery products are currently in clinical development.  The company has raised approximately  $40 million  in financing from Safar Partners, Stonehenge Growth Equity, Armory Square Ventures, prominent angel investors and the National Science Foundation.  The team is composed of serial entrepreneurs with multiple exits as well as ophthalmic industry veterans who pioneered a number of new ophthalmic technology categories.